Haleon PLC

Haleon Plc provides personal healthcare products. The firm focus on consumer healthcare and driven by its purpose of delivering better everyday health with humanity. Its brands are built on science, innovation and human understanding and are trusted by millions of consumers globally. The company is headquartered in Brentford, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haleon Plc engages in the provision of personal healthcare products. The firm focuses on consumer healthcare. It operates under the following geographical segments: North America, EMEA and LatAm, and Asia Pacific. The company was founded on July 18, 2022 and is headquartered in Weybridge, the United Kingdom.

International Consolidated Airlines Group SA

Ocado Group PLC

Scheduled company news is a little quieter after last week's rush of bank, mining and US tech updates, but there is still a decent stack of household names updating. Bunzl, the biggest company nobody has heard of, kicks off the week with British Airways owner IAG, GSK spin-off Haleon, Ocado and Pearson all due as well.

British Airways, Ocado and Haleon to set next week's pace

The leader in cold sore relief will shine a light on the condition, rewarding one cold sore sufferer with the limited edition, sparkling accessory. WARREN, N.J.

Abreva Drops One-of-a-Kind Pair of Diamond Lips, Inspired by the Cold Sore Experience

Analysts are divided over fast-moving consumer goods big cap Haleon PLC (LSE:HLN, NYSE:HLN)'s prospects prior to the FTSE 100-listed firm's annual results next month. According to Jefferies, Haleon is well-positioned to exceed both its organic sales and operating profit growth forecasts, placing it at the higher end of its full-year guidance.

Haleon garners mixed impressions from City analysts

Haleon is recalling some lots of its adult cough syrup Robitussin because of microbial contamination, the U.S. Food and Drug Administration (FDA) has said.

Haleon to recall batches of some adult cough syrups due to contamination

Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare company, confirmed the sale of its lip balm brand ChapStick for US$430 million, a company statement revealed. Suave Brands, a portfolio company of Yellow Wood Partners, will also provide Haleon with a minority stake worth around US$80 million as part of the deal.

Haleon sells ChapStick brand in bid to relieve debt pile

Britain's Haleon said it had agreed to sell lip balm brand ChapStick to a company owned by private equity firm Yellow Wood Partners for around $430 million in cash and a stake valued at around $80 million in the buyer.

Haleon to sell ChapStick to Yellow Wood for about $510 million

BOSTON , Jan. 25, 2024 /PRNewswire/ -- Yellow Wood Partners ("Yellow Wood"), a Boston-based private equity firm focused on investing in consumer brands and companies, today announced that its portfolio company Suave Brands Company has signed a binding offer to acquire the ChapStick brand from Haleon (LSE / NYSE: HLN), a global leader in consumer health. The transaction is intended to close in the first half of 2024 upon completion of customary closing and regulatory approvals.

Yellow Wood Partners Portfolio Company Suave Brands Company Acquires ChapStick from Haleon

A third study from the COSMOS trial, COSMOS-Clinic, demonstrates consistent findings that taking Centrum Silver multivitamin daily benefits memory among older adults. WARREN, N.J.

New Research Affirms the Positive Impact of Centrum Silver on Memory in Older Adults

Haleon PLC (LSE:HLN, NYSE:HLN) was the biggest faller on the FTSE 100 on Wednesday morning after JPMorgan fired off a warning shot ahead of the Sensodyne and Panadol maker's annual results next month.  Having delivered strong volumes versus sector peers in the consumer staples sector over the past two years, the investment bank now expects the top line to disappoint as the tailwinds that boosted its over-the-counter divisions abate.

Haleon slides as forecasts trimmed ahead of full-year results

TUMS® Prop Bites allows fans to decide which foods have won America's hearts and stomachs for a shot at a share of $10,000 prize pool WARREN, N.J. , Jan. 17, 2024 /PRNewswire/ -- In honor of the biggest day in football, TUMS® is collaborating with DraftKings to launch TUMS® Prop Bites, a first-of-its kind platform where fans can make their free food picks and see how they stack up against the rest of the nation for a shot to win cash prizes.

TUMS® Teams Up with DraftKings and Desus Nice to Launch TUMS® Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time

GlaxoSmithKline

GSK PLC (LSE:GSK, NYSE:GSK) said it completed the sale of 300 million shares in Haleon, the consumer health giant, netting £978 million, or $1.23 billion, in the process. The sum is around $200 million shy of the cash it is handing over to take over Aiolos Bio, the respiratory and inflammatory diseases specialists.

GSK nets £978m from Haleon share sale

British drugmaker GSK said on Wednesday it had raised 978 million pounds ($1.24 billion) from a discounted stake sale in Haleon , cutting its shareholding to 4.2% in the world's largest standalone consumer healthcare firm.

GSK raises $1.24 bln from latest Haleon stake sale

GSK will sell a 3.2% stake, or about 300 million shares, in its spun-off consumer healthcare business Haleon , the British drugmaker said on Tuesday.

GSK to sell 3.2% stake in spin-off Haleon

The Official TUMS Bag is Available on Amazon and nikolasbentelstudio.com – Hurry, Before They Sell Out!  WARREN, N.J.

TUMS Partners with Designer Nik Bentel to Launch Limited Edition TUMS Bag to Fuse Food, Fashion and Heartburn Relief

Bausch Health Companies Inc

Subaru Corp

Known for historically being the strongest month of the year for U.S. stocks, the Dow and S&P 500 both gained nearly 9% last month. The Nasdaq, almost 11%.

3 cheap 'stock'-ing stuffers Wall Street is bullish on

Haleon is a leading consumer healthcare company operating in the OTC medication, vitamins, minerals & supplements, and oral health segments. The company's strong brand and product moat make it less susceptible to recession impact, and its geographic diversification provides a stable financial base for growth. Despite challenges in the North American market and ongoing economic uncertainty, Haleon is trading at a significantly undervalued level with a potential upside of c.20%.

Haleon's Long-Term Growth Prospects Look Healthy On Solid Macro Trends

Broadstone Net Lease

Bank of Nova Scotia

Chimera Investment

Canadian Imperial Bank of Commerce

Cisco Systems

Diageo

Illinois Tool Works

Leggett & Platt

McDonald's

MDU Resources Group

Medical Properties Trust

NetApp

Realty Income Corp

Orion Office REIT

Paramount Global

Philip Morris

Invesco S&P 500 High Dividend Low Volatility ETF

TotalEnergies SE

Visa

Vanguard Dividend Appreciation ETF

Vanguard S&P 500 ETF

Growing dividend income takes time and consistency. The Fed paused a rate hike in September and will likely remain in a holding pattern for November, with a modest chance of an increase in December. Increase passive income by consistently investing in the market and letting dividend reinvestment do the trick.

Dividend Income Summary: Lanny's October 2023 Summary

More than three in five (63%) people in the UK experience barriers to health inclusion People in UK, Canada and France face the longest waiting times to see a GP Health inclusivity scores fall worldwide with addition of lived experience data in Economist Impact's Health Inclusivity Index, supported by Haleon - exposing glaring policy-practice gap in wealthy countries LONDON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- More than three in five (63%) people in the UK experience health exclusion according to phase two of the Economist Impact's Health Inclusivity Index, released today. The Index - which measures the extent and experience of health inclusion across 40 countries and 42,000 people worldwide - reveals that the UK's score has fallen by 13% this year, slipping from first to third place in the global rankings.

UK falls to third place in global Health Inclusivity Index

Phase two of Economist Impact's Health Inclusivity Index, supported by Haleon, measures experience of health inclusion across 42,000 people in 40 countries Health inclusivity scores fall worldwide with addition of lived experience data, exposing glaring policy-practice gap in wealthy countries 66% of survey respondents experience barriers to health inclusion, with the most vulnerable worst affected Index reveals stark generational divide with Gen Z and Millennials experiencing greater barriers to access and higher levels of discrimination LONDON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- More than three in five people worldwide experience health exclusion, with vulnerable and younger populations the worst affected, according to phase two of the global Health Inclusivity Index from Economist Impact, supported by consumer health company Haleon. This year's study – which measures the extent and experience of health inclusion across 40 countries and 42,000 people – revealed that 66% of those surveyed face at least one barrier in accessing healthcare services.

Health exclusion affects more than three in five people globally

Haleon sells health products internationally with stable operations and modest growth through a good performance in oral health products, and growth in Asia Pacific. The company's financials have remained solid with stable revenue increases and high EBIT margins. The stock seems to be priced for the good financials - I don't see significant upside or downside for the stock at the moment.

Haleon: A Stable Pick

The second phase of the index, supported by Haleon, assesses governments' efforts across 40 countries to ensure that good health is accessible to all individuals LONDON , Nov. 20, 2023 /PRNewswire/ -- Economist Impact, an arm of The Economist Group that works with organisations globally to further their missions, today launched phase two of the Health Inclusivity Index , supported by Haleon  (LSE / NYSE: HLN), a global leader in consumer health. This phase's results show health inclusivity falling worldwide, and notably Britain falling from its top spot in phase one.

Britain falls from top spot in Economist Impact's latest Health Inclusivity Index

Haleon plc is a promising company in the personal care products sector, with a low beta and cheap valuation. The company operates globally and has leading brands in oral health, painkillers, and vitamins. Haleon's ownership structure is interconnected with Pfizer and GSK, but divestitures could increase competitive pressures.

The Investment Case For Haleon: Steady Shareholder Value Accumulation

Haleon PLC (LSE:HLN, NYSE:HLN)'s stock took a 2.6% hit in early trading, erasing roughly £800 million in market value, following the company's third-quarter revenue and profit report that fell short of market expectations. For the quarter ending September 30, Haleon reported a 5% organic increase in revenue, totalling £2.79 billion, slightly below the anticipated £2.83 billion.

Haleon down as sales and earnings marginally undershoot - maintains full-year outlook

Consumer healthcare company Haleon posted higher third-quarter revenue and stuck by its full-year forecasts on Thursday, helped by price hikes and resilient demand for its painkillers, cold and flu tablets, and oral health products.

Advil maker Haleon's quarterly revenue rises on price hikes, strong demand

Haleon's third-quarter update won't be game-changing but will support a longer-term debt reduction thesis, suggests Citi. Organic sales growth should be 5.2%  prices +4.7%), says the US bank, with a likely 3.9% increase forecast for the fourth quarter with flu volumes the drag.

News for Haleon PLC Stock (HLN)